Document is current

Article History

Received: 20 September 2024

Accepted: 2 December 2024

First Online: 12 December 2024

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethics Review Board in Gothenburg (Approval Numbers: 869 − 13, 006–14, and T703-14). All participant and/or their close relatives gave written informed consent to participate in the study.

: Not applicable.

: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). SK has served at scientific advisory boards, speaker and / or as consultant for Roche, Geras Solutions, Optoceutics, Biogen and Bioarctic.